Claims for Patent: 5,942,390

Summary for Patent: 5,942,390

Title:	Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
Abstract:	A novel, differential association between allele 2 of the variable number of tandem repeats polymorphism at intron 2 of the human IL-1 receptor antagonist gene and ulcerative colitis in humans of Jewish ancestry has been discovered. In accordance with the present invention, there is provided methods of screening for ulcerative colitis in human subjects of Jewish ancestry comprising detecting the presence or absence of nucleic acid of the subject encoding allele 2 of the variable number of tandem repeats polymorphism at intron 2 of the human IL-1 receptor antagonist gene, wherein the presence of nucleic acid encoding allele 2 is indicative of ulcerative colitis. Kits useful for screening for ulcerative colitis in human subjects of Jewish ancestry are also provided.
Inventor(s):	Cominelli; Fabio (Charlottesville, VA), Pizarro; Theresa (Charlottesville, VA), Rotter; Jerome I. (Los Angeles, CA), Yang; Huiying (Cerritos, CA)
Assignee:	Cedars-Sinai Medical Center (Los Angeles, CA)
Application Number:	08/587,911
Patent Claims:	1. A method of diagnosing a predisposition to ulcerative colitis in a human of Jewish ancestry, comprising obtaining from a human a biological sample comprising nucleated cells; assessing the presence in the sample of a polynucleotide comprising at least a segment of allele 2 of the variable number of tandem repeats (VNTR) polymorphism at intron 2 of the human interleukin-1 receptor antagonist (IL-1ra ) gene; and determining whether the human is of Jewish ancestry; and diagnosing a predisposition to ulcerative colitis (UC) when both the allele 2 polynucleotide, or fragments thereof, is detected and the human is of Jewish ancestry. 2. The method of claim 1, wherein the presence of the allele 2 polynucleotide is assessed by measuring the length of the polynucleotide, and comparing it to a control selected from the group consisting of positive and negative controls. 3. The method of claim 1, wherein the presence of the allele 2 polynucleotide is assessed by determining the sequence of the polynucleotide, and comparing it to a control selected from the group consisting of positive and negative controls. 4. The method of claim 1, wherein the presence of the allele 2 polynucleotide is assessed by determining whether a DNA of the human subject possesses a defining characteristics of allele 2 selected from the group consisting of size, specific sequence, number of sequence repeats, ability to hybridize with a labeled probe under specific hybridization conditions, and ability to bind with an antibody specific for a particular allele, wherein these characteristics are compared to a positive control which defines the same or similar characteristic for allele 2 of the VNTR polymorphism and/or a negative control with defines the same or similar characteristic for an allele of the VNTR polymorphism not known to be associated with UC in a person of Jewish ancestry. 5. The method of claim 3, wherein the presence of the allele 2 polynucleotide is assessed by determining the number of sequence repeats in the polynucleotide, and comparing it to a control selected from the group consisting of positive and negative controls. 6. The method of claim 1, wherein the nucleated cells in the sample comprise mononuclear blood cells. 7. The method of claim 1, wherein the ancestry of the human is determined as Jewish when at least one biologically-related grandparent of the human is of Jewish ancestry. 8. The method of claim 1, further comprising determining whether the human of Jewish ancestry is of Caucasian ancestry. 9. The method of claim 8, further comprising determining whether the human of Caucasian ancestry is of Ashkenazi ancestry. 10. The method of claim 1, wherein the allele 2 polynucleotide is detected by allele-specific nucleotide probing, and compared to a control selected from the group consisting of positive and negative controls. 11. The method of claim 1, wherein the allele 2 polynucleotide is detected by methods selected from the group consisting of differential restriction endonuclease digestion, electrophoresis, automated sequencing, allele-specific probing, and ligase-mediated gene detection and compared to a control selected from the group consisting of positive and negative controls. 12. The method of claim 2, wherein the length of the allele 2 polypeptide is detected; and the polynucleotide control is selected from the group consisting of a 240 nucleotides long positive control, and 325, 410, 500 and 595 nucleotides long negative controls. 13. The method of claim 1, wherein the polynucleotide is detected by amplifying cellular genomic DNA; and identifying the allele 2 polynucleotide of the VNTR polymorphism of the human IL-1ra gene. 14. The method of claim 13, wherein the amplifying step is conducted with primers specific for a polynucleotide encoding allele 2 of the VNTR polymorphism of the human IL-1ra gene. 15. The method of claim 14, wherein at least one primer is selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, and fragments thereof. 16. The method of claim 1, wherein the polynucleotide is detected by sequencing the polynucleotide encoding a fragment of intron 2 of the VNTR allele of the IL-1ra gene; and identifying the allele present by comparison to a control. 17. A method of determining whether an inflammatory bowel disease (IBD) patient of Jewish ancestry has ulcerative colitis, comprising the method of claim 1, wherein the biological sample is obtained from a patient afflicted with IBD. 18. A method of distinguishing whether a human of Jewish ancestry has a predisposition to ulcerative colitis or Crohn's disease, comprising obtaining from a human a biological sample comprising nucleated cells; assessing the presence in the sample of a polynucleotide comprising at least a segment of allele 2 of the variable number of tandem repeats (VNTR) polymorphism at the interleukin-1 receptor antagonist (IL-1ra) gene; determining whether the human is of Jewish ancestry; and diagnosing a predisposition to ulcerative colitis when both the allele 2 polynucleotide is detected and the human is of Jewish ancestry. 19. A kit for diagnosing a predisposition to UC in humans of Jewish ancestry, comprising at least one primer specific to a polynucleotide comprising a segment of intron 2 of allele 2 of the variable number of tandem repeats (VNTR) polymorphism at the interleukin-1 receptor antagonist (IL-1ra) gene; and instructions for its use with nucleic acids of humans of Jewish ancestry. 20. The kit of claim 19, wherein the primers are about 10 to about 30 nucleotide long. 21. The kit of claim 19, wherein at least one of the primers is complementary to a nucleotide segment up-stream from the segment encoding the VNTR polymorphism. 22. The kit of claim 19, wherein at least one of the primers is complementary to a nucleotide segment down-stream from the segment encoding the VNTR polymorphism. 23. The kit of claim 19, wherein the polynucleotide comprises a segment of intron 2. 24. The kit of claim 23, wherein the polynucleotide comprises intron 2. 25. The kit of claim 19, in packaged form. 26. The kit of claim 19, further comprising an agent selected from the group consisting of DNA markers; DNA selected from the group consisting of primers and probes to, and DNA segments of, intron 2 of allele 1, 3, 4, and 5 of the IL-1ra gene encoding the VNTR polymorphism; a control selected from the group consisting of positive and negative controls for allele 2 of the IL-1ra gene fragment encoding the VNTR polymorphism; and DNA polymerizing enzyme(s). 27. The kit of claim 26, wherein the DNA markers comprise markers about 100 to about 600 nucleotides long. 28. The kit of claim 26, wherein the positive control comprises allele 2 of the IL-1ra gene fragment encoding the VNTR polymorphism. 29. The kit of claim 27, wherein the negative control comprises a DNA fragment selected form the group consisting of DNA fragments of allele 1, allele 3, allele 4, and allele 5 of the IL-1ra gene fragment encoding the VNTR polymorphism. 30. The kit of claim 19, wherein the primers are nucleic acids specified by SEQ. ID. NO.: 1 and/or SEQ. ID. NO.:2. 31. The method of claim 1, further comprising the step of using a standard diagnostic test for ulcerative colitis, wherein ulcerative colitis is thereby distinguished from Crohn's disease.

Details for Patent 5,942,390

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26